+ 44 (0) 1709 361 241 info@kirkstall.com
Kirkstall - Quasi Vivo Logo

Scientific Advisory Panel

Saving Lives Through Better Science™

Kirkstall Ltd

Professor J Malcolm Wilkinson

Malcolm retired as CEO of Kirkstall Ltd, one of the world’s leading Organ on a Chip companies, in 2019. He is now busier than ever helping research organisations and charities working to replace the use of animals. Previously in his career he had senior roles in both R&D and sales and marketing. He founded a consulting company which supported spin-outs from Universities and raised over $15 million from Venture capital and regional development funds.

He was a visiting Lecturer for FSRM, Neuchatel, Switzerland, on the subject of Micro and Nanotechnology in Biomedical Engineering for over 10 years and was appointed as a Visiting Professor in the Department of Biomedical Engineering at Sheffield University in 2019.  

Dr Wilkinson is co-author on several papers on in-vitro models of toxicity and a contributing editor of a recently published book on In-Vitro Testing.

After studying biology/zoology at the Leopold-Franzens-University of Innsbruck and my PhD at the Institute of Theoretical Surgery, I started working on host-pathogen interactions as a post-doc at the Institute for Hygiene and Medical Microbiology at the Medical University of Innsbruck (MUI). After a stay abroad in 2008/2009 at University College London, I set up my work group at the Institute for Hygiene and Medical Microbiology with third-party funding and have been successfully working for many years with my group (immunology and cell biology) on host-pathogen interactions and infection susceptibility within 3D models.

We lay a special focus on the use of relevant, human 3D cell culture systems and primary cells in order to simulate the course of an infection as ‘realistically as possible in the petri dish’ and thus gain insights that are not revealed when using 2D cultures or degenerated cell lines. From 2012 to 2019, I worked as an associate professor and deputy director at the Institute of Hygiene and Medical Microbiology at MUI and have a university professorship in infection biology since 2020. Over the years, I have successfully acquired competitive third-party funding (FWF, NIH, ÖNB), have published continuously (48 publications in the last 5 years), am committed to teaching infectiology and immunology, and have a self-designed course on alternatives to animal experiments in biomedical research in the MUI curriculum to teach junior scientists on the opportunities of human-centered models.

Doris Wilflingseder

Doris is the Professor of Infection Biology at the Medical University of Innsbruck.
Kirkstall Ltd

Prof Martin J. D. Clift, a Professor of Particle and Fibre Toxicology at Swansea University (SU) Medical School, is globally recognised for using advanced in vitro lung model systems to assess the toxicology of particles and fibres (>165 publications; h-index 38; >5970 citations). His expertise is upon air pollution as well as in vitro systems/(nano)particle and fibre toxicology. His research has focused on in vitro models, incorporating fluid-flow dynamics, that mimic the in vivo environment to gain a mechanistic understanding of how particles/fibres materials may, potentially, be adverse towards human health. He has been/is PI on research projects totalling >£5 million, with a further >£30million as Co-I (since 2011). He is a full member of the UK Government Committee of Medical Effects of Air Pollutants (COMEAP), as well as a member of the Sub-Scientific Committee of the British Toxicology Society (BTS) and a Scientific Board member of Animal Free Research (AfR) UK. He also acts as Editor-in-Chief (Fibers), Senior/Associate Editor (Particle Fibre Toxicology; Journal of Nanobiotechnology) and Editorial Board Member for numerous journals.


Dr. Harvey J. Clewell

Dr. Harvey J. Clewell is a research scientist with over forty-five years of experience in environmental quality and toxicology research, chemical risk assessment and hazardous materials management.  He is currently a Principal Consultant with Ramboll US Consulting, Inc.  He received a Masters in Chemistry from Washington University, St. Louis, and a PhD in Toxicology from the University of Utrecht, the Netherlands.  He is a Diplomate of the American Board of Toxicology and a Fellow of the Academy of Toxicological Sciences.   He has gained an international reputation for his work on the incorporation of mechanistic data and mode of action information into chemical risk assessments, having played a seminal role in the use of physiologically based pharmacokinetic (PBPK) modeling in cancer and non-cancer assessments.  He has authored more than 200 peer-reviewed scientific publications and book chapters on the use of pharmacokinetics, dose-response analysis, genomics and new alternative methods (NAMs) in risk assessment.  In 2007 the Society of Toxicology recognized Dr. Clewell with the Arnold J. Lehman Award for major contributions to chemical safety and risk assessment.  He served as a member of the ECVAM Scientific Advisory Committee from 2012 to 2016.

Sign Up For Our Newsletter

For all the latest from us, including interesting research videos and more, please subscribe to our newsletter below.
All data is stored in accordance with our privacy policy .

    Contact Us

    Address: Kirkstall, Ltd York House,
    Outgang Lane, York
    North Yorkshire, YO19 5UP

    Phone: + 44 (0) 1709 361 241

    Business Hours: Monday to Friday 9:00am-5:00pm (UK Time)